Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tideglusib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B known ✓ | P49841 | 5/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | RGS4 | P49798 | 13/20 | 0.62 |
| ▸ | RGS8 | P57771 | 13/20 | 0.62 |
| ▸ | GSK3A | P49840 | 3/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tideglusib SCHEMBL29357303 | 1.00 | GSK3B (1.00) | GSK3BHDAC6RGS4RGS8GSK3A | |
| SCHEMBL29239083 | 0.91 | GSK3B (0.83) | GSK3BHDAC6RGS4RGS8GSK3A | |
| SCHEMBL29239080 | 0.90 | GSK3B (0.81) | GSK3BHDAC6RGS4RGS8GSK3A | |
| SCHEMBL29239076 | 0.90 | GSK3B (0.81) | GSK3BHDAC6RGS4RGS8 | |
| SCHEMBL29239075 | 0.90 | GSK3B (0.81) | GSK3BHDAC6RGS4RGS8PRKCA | |
| SCHEMBL29239096 | 0.89 | GSK3B (0.80) | GSK3BHDAC6RGS4RGS8GSK3A | |
| SCHEMBL29239085 | 0.87 | GSK3B (0.77) | GSK3BHDAC6RGS4RGS8GSK3A | |
| SCHEMBL30893121 | 0.87 | GSK3B (0.77) | GSK3BHDAC6RGS4RGS8GSK3A | |
| SCHEMBL30893119 | 0.87 | GSK3B (0.76) | GSK3BHDAC6RGS4RGS8DAPK3 | |
| SCHEMBL29239068 | 0.87 | GSK3B (0.76) | GSK3BHDAC6RGS4RGS8DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269129-A1 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | THE BROAD INSTITUTE, INC. | 2024-08-15 | — | — | US | claimed |
| EP-4340832-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | Amo Pharma Ltd. (GB) | 2024-03-27 | — | — | EP | claimed |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2023-08-03 | — | — | US | claimed |
| US-11590110-B2 | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2023-02-28 | — | — | US | claimed |
| US-20220387399-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2022-12-08 | — | — | US | claimed |
| US-10744141-B2 | Compositions and methods for treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-08-18 | — | — | US | claimed |
| US-20200085797-A1 | Compositions And Methods For Reactivating Latent Immunodeficiency Virus Using A Gsk-3 Inhibitor | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2020-03-19 | — | — | US | claimed |
| US-20190247396-A1 | DENTAL TREATMENT | KING'S COLLEGE LONDON (GB) | 2019-08-15 | — | — | US | claimed |
| WO-2018226721-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS USING A GSK-3 INHIBITOR | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-12-13 | — | — | WO | claimed |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY | 2018-07-05 | — | — | US | claimed |
| EP-3313819-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Case Western Reserve University (US) | 2018-05-02 | — | — | EP | claimed |
| US-20170157038-A1 | OPHTHALMIC DRUG DELIVERY METHOD | PEYMAN GHOLAM A (US) | 2017-06-08 | — | — | US | claimed |
| WO-2016210134-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-12-29 | — | — | WO | claimed |
| US-20120010148-A1 | COMBINATION THERAPIES USING NAP | ALLON THERAPEUTICS INC. (CA) | 2012-01-12 | — | — | US | claimed |
| WO-2011151359-A1 | COMBINED TREATMENT WITH A CHOLINESTERASE INHIBITOR AND A THIADIAZOLIDINEDIONE DERIVATIVE | NOSCIRA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| EP-2381955-A1 | COMBINATION THERAPIES USING NAP | Ramot at Tel-Aviv University Ltd. (IL) | 2011-11-02 | — | — | EP | claimed |
| WO-2010075635-A1 | COMBINATION THERAPIES USING NAP | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2010-07-08 | — | — | WO | claimed |
| WO-2006045581-A1 | THE USE OF 1, 2, 4-THIADIAZOLIDINE-3, 5-DIONES AS PPAR ACTIVATORS | NEUROPHARMA, S.A. (ES) | 2006-05-04 | — | — | WO | claimed |
| US-20260014139-A1 | Femtosecond Laser Treatment Methods | PEYMAN GHOLAM A (US) | 2026-01-15 | — | — | US | disclosed |
| US-20050222220-A1 | GSK-3 inhibitors | NEUROPHARMA, S.A. (ES) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387399-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | TRDMT1, HNRNPDL, HNRNPD | GSK3B 3391/4885HDAC6 828/4885RGS4 3507/4885 |
| US-20260014139-A1 | Femtosecond Laser Treatment Methods | GSK3B, GSK3A, CTNND1 | GSK3B 1/4885HDAC6 1013/4885RGS4 3573/4885 |
| US-20240269129-A1 | GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS FOR TREATING CTNNB1 SYNDROME | GSK3B, GSK3A, CTNNB1 | GSK3B 1/4885HDAC6 814/4885RGS4 3514/4885 |
| US-20180185382-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | PPP2CA, PPP3CA, PPP4C | GSK3B 215/4885HDAC6 51/4885RGS4 2616/4885 |
| US-10744141-B2 | Compositions and methods for treating cancer | PPP2CA, PPP3CA, PPP4C | GSK3B 215/4885HDAC6 51/4885RGS4 2616/4885 |
| US-20200085797-A1 | Compositions And Methods For Reactivating Latent Immunodeficiency Virus Using A Gsk-3 Inhibitor | GSK3B, GSK3A, GSKIP | GSK3B 1/4885HDAC6 2491/4885RGS4 4174/4885 |
| US-20190247396-A1 | DENTAL TREATMENT | GSK3B, GSK3A, GSKIP | GSK3B 1/4885HDAC6 611/4885RGS4 3150/4885 |
| US-11590110-B2 | Compositions and methods for reactivating latent immunodeficiency virus using a GSK-3 inhibitor | GSK3B, GSK3A, GSKIP | GSK3B 1/4885HDAC6 2491/4885RGS4 4174/4885 |
| US-20050222220-A1 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885HDAC6 1409/4885RGS4 4483/4885 |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | TRDMT1, HNRNPDL, HNRNPD | GSK3B 3391/4885HDAC6 828/4885RGS4 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.